Herath CB - Search Results

1

Development and Progression of Non-Alcoholic Fatty Liver Disease: The Role of Advanced Glycation End Products.

Fernando DH, Forbes JM, Angus PW, Herath CB. Fernando DH, et al. Among authors: herath cb. Int J Mol Sci. 2019 Oct 11;20(20):5037. doi: 10.3390/ijms20205037. Int J Mol Sci. 2019. PMID: 31614491 Free PMC article. Review.

2

Advanced glycation end products augment experimental hepatic fibrosis.

Goodwin M, Herath C, Jia Z, Leung C, Coughlan MT, Forbes J, Angus P. Goodwin M, et al. J Gastroenterol Hepatol. 2013 Feb;28(2):369-76. doi: 10.1111/jgh.12042. J Gastroenterol Hepatol. 2013. PMID: 23173780

3

Increased liver AGEs induce hepatic injury mediated through an OST48 pathway.

Zhuang A, Yap FY, Bruce C, Leung C, Plan MR, Sullivan MA, Herath C, McCarthy D, Sourris KC, Kantharidis P, Coughlan MT, Febbraio MA, Hodson MP, Watt MJ, Angus P, Schulz BL, Forbes JM. Zhuang A, et al. Sci Rep. 2017 Sep 25;7(1):12292. doi: 10.1038/s41598-017-12548-4. Sci Rep. 2017. PMID: 28947796 Free PMC article.

4

Dietary glycotoxins exacerbate progression of experimental fatty liver disease.

Leung C, Herath CB, Jia Z, Goodwin M, Mak KY, Watt MJ, Forbes JM, Angus PW. Leung C, et al. Among authors: herath cb. J Hepatol. 2014 Apr;60(4):832-8. doi: 10.1016/j.jhep.2013.11.033. Epub 2013 Dec 6. J Hepatol. 2014. PMID: 24316518

5

Dietary advanced glycation end-products aggravate non-alcoholic fatty liver disease.

Leung C, Herath CB, Jia Z, Andrikopoulos S, Brown BE, Davies MJ, Rivera LR, Furness JB, Forbes JM, Angus PW. Leung C, et al. Among authors: herath cb. World J Gastroenterol. 2016 Sep 21;22(35):8026-40. doi: 10.3748/wjg.v22.i35.8026. World J Gastroenterol. 2016. PMID: 27672297 Free PMC article.

6

Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.

Lubel JS, Herath CB, Burrell LM, Angus PW. Lubel JS, et al. Among authors: herath cb. J Gastroenterol Hepatol. 2008 Sep;23(9):1327-38. doi: 10.1111/j.1440-1746.2008.05461.x. Epub 2008 Jun 28. J Gastroenterol Hepatol. 2008. PMID: 18557800 Free PMC article. Review.

7

Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.

Grace JA, Herath CB, Mak KY, Burrell LM, Angus PW. Grace JA, et al. Among authors: herath cb. Clin Sci (Lond). 2012 Aug 1;123(4):225-39. doi: 10.1042/CS20120030. Clin Sci (Lond). 2012. PMID: 22548407 Review.

8

The Adeno-associated Virus - A Safe and Promising Vehicle for Liverspecific Gene Therapy of Inherited and Non-inherited Disorders.

Mak KY, Rajapaksha IG, Angus PW, Herath CB. Mak KY, et al. Among authors: herath cb. Curr Gene Ther. 2017;17(1):4-16. doi: 10.2174/1566523217666170314141931. Curr Gene Ther. 2017. PMID: 28292253

9

The small molecule drug diminazene aceturate inhibits liver injury and biliary fibrosis in mice.

Rajapaksha IG, Mak KY, Huang P, Burrell LM, Angus PW, Herath CB. Rajapaksha IG, et al. Among authors: herath cb. Sci Rep. 2018 Jul 5;8(1):10175. doi: 10.1038/s41598-018-28490-y. Sci Rep. 2018. PMID: 29977014 Free PMC article.

10

Current therapies and novel approaches for biliary diseases.

Rajapaksha IG, Angus PW, Herath CB. Rajapaksha IG, et al. Among authors: herath cb. World J Gastrointest Pathophysiol. 2019 Jan 5;10(1):1-10. doi: 10.4291/wjgp.v10.i1.1. World J Gastrointest Pathophysiol. 2019. PMID: 30622832 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

56 results

Search Page